CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 83 enrolled
Drug / intervention
placebo/dalfampridine-ER +1 moredrug
Likely dose
placebo/dalfampridine-ER 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01605825
NCT01605825Phase 2Completed
CompareCT.gov

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

Acorda Therapeutics·interventional·Posted May 25, 2012·Updated Jan 22, 2016

In Brief

A Phase 2 clinical trial evaluating placebo/dalfampridine-ER and dalfampridine-ER/placebo for Ischemic Stroke. Completed, enrolled 83 participants across 20 sites.

Detailed Summary

This is a multi-center, safety and tolerability study in subjects with chronic stable sensorimotor deficits after ischemic stroke. It has been designed as a double-blind, placebo-controlled, 2-period crossover study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 25, 2012
Enrollment StartMay 1, 2012
Primary CompletionFeb 1, 2013
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.1 years ago

Interventions

placebo/dalfampridine-ERdrug

Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart

dalfampridine-ER/placebodrug

Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart